Chronic leukemia CML, diagnosed, wants to use the second generation TKI medicine. I heard that there is a new drug Flumatinib. How about it?

Flumatinib, a new drug for chronic leukemia CML, has only been on the market for a few months, but all new drugs have to go through phase III clinical trials before they can be approved. Safety is the main observation index in the third phase of clinical trials. From the clinical trial data, compared with several second-generation drugs already on the market, flumatinib has better safety: therefore, it belongs to the second generation+. In addition, from the mechanism of drug action, the binding and specificity of flumatinib to the target is stronger than that of nilotinib and dasatinib, so there are fewer adverse reactions in theory. Objectively speaking, the situation you mentioned has also happened in history. After the new drug went on the market, it was delisted due to serious adverse reactions, but it was an accidental small probability event.